IRIS
MORE', SONIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.490
AS - Asia 1.041
EU - Europa 733
SA - Sud America 329
AF - Africa 77
OC - Oceania 2
Totale 3.672
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.434
VN - Vietnam 303
BR - Brasile 260
SG - Singapore 247
IT - Italia 215
CN - Cina 179
RU - Federazione Russa 169
HK - Hong Kong 153
DE - Germania 77
FR - Francia 70
FI - Finlandia 51
IN - India 39
CI - Costa d'Avorio 35
AR - Argentina 33
GB - Regno Unito 29
MX - Messico 27
IE - Irlanda 23
NL - Olanda 23
AT - Austria 18
BD - Bangladesh 17
CA - Canada 17
JP - Giappone 13
MA - Marocco 12
IQ - Iraq 11
ZA - Sudafrica 11
ID - Indonesia 10
SE - Svezia 10
SA - Arabia Saudita 9
TR - Turchia 9
CO - Colombia 8
EC - Ecuador 8
PL - Polonia 8
UA - Ucraina 8
VE - Venezuela 8
AE - Emirati Arabi Uniti 7
UZ - Uzbekistan 7
ES - Italia 6
PY - Paraguay 6
PK - Pakistan 5
CR - Costa Rica 4
KE - Kenya 4
KR - Corea 4
MY - Malesia 4
PE - Perù 4
SN - Senegal 4
TN - Tunisia 4
BE - Belgio 3
DK - Danimarca 3
HU - Ungheria 3
JO - Giordania 3
TH - Thailandia 3
TW - Taiwan 3
AU - Australia 2
BH - Bahrain 2
CH - Svizzera 2
DZ - Algeria 2
EG - Egitto 2
HN - Honduras 2
HR - Croazia 2
LT - Lituania 2
NP - Nepal 2
PH - Filippine 2
RO - Romania 2
SV - El Salvador 2
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GE - Georgia 1
GI - Gibilterra 1
GR - Grecia 1
GT - Guatemala 1
IL - Israele 1
IS - Islanda 1
KH - Cambogia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MT - Malta 1
MU - Mauritius 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 3.672
Salva come PNG Salva come JPEG
Città #
Ashburn 374
Dallas 372
Hong Kong 150
Singapore 150
San Jose 120
Ho Chi Minh City 110
Hanoi 61
Boardman 50
Council Bluffs 43
Beijing 36
Munich 36
Abidjan 35
Helsinki 35
Lauterbourg 35
The Dalles 35
Los Angeles 34
São Paulo 28
Moscow 27
New York 25
Dublin 23
Hefei 23
Chandler 22
Rome 20
Frankfurt am Main 18
Chicago 16
Da Nang 16
Denver 15
Milan 15
Turku 15
Nuremberg 14
Buffalo 13
Santa Clara 13
Orem 12
Mexico City 11
Amsterdam 10
Chennai 10
Guangzhou 10
Haiphong 10
Ancona 9
Biên Hòa 9
Brooklyn 9
Tokyo 9
Montreal 8
Warsaw 8
Bari 7
Bologna 7
Hải Dương 7
Johannesburg 7
Phoenix 7
Xi'an 7
Can Tho 6
Houston 6
Lawrence 6
Manchester 6
Princeton 6
Rio de Janeiro 6
Shenzhen 6
Tashkent 6
Turin 6
Atlanta 5
Baghdad 5
Boston 5
Curitiba 5
Fairfield 5
Falconara Marittima 5
Jiujiang 5
North Charleston 5
Poplar 5
Porto Alegre 5
Redmond 5
Salt Lake City 5
Thái Nguyên 5
Belo Horizonte 4
Buenos Aires 4
Camden 4
Caracas 4
Dakar 4
Huế 4
London 4
Mumbai 4
New Delhi 4
Osimo 4
Pescara 4
Ribeirão Preto 4
San Francisco 4
Santo André 4
Seattle 4
Tunis 4
Vienna 4
Washington 4
Yiwu 4
Bogotá 3
Brasília 3
Brussels 3
Corridonia 3
Florence 3
Guarulhos 3
Holstebro 3
Lima 3
Magnesia ad Sipylum 3
Totale 2.358
Salva come PNG Salva come JPEG
Nome #
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial 211
Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations 148
POOR RESPONSE TO FIRST BNT162B2 SARS-COV-2 VACCINE DOSE IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT 132
Real‐world assessment of treatment patterns and outcomes in patients with relapsed‐refractory multiple myeloma in an Italian haematological tertiary care centre 127
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 125
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study 119
NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES 118
Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study 111
Current Main Topics in Multiple Myeloma 110
Breast Cancer With Release of Tumor Cells in Peripheral Blood Mimicking Acute Myeloid Leukemia 108
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma 106
Developments in consolidation and maintenance strategies in post-remission multiple myeloma 106
Editorial: Reviews in hematologic malignancies 104
Frequency and Risk Factors for Venous Thromboembolism Among Patients with Multiple Myeloma or Aggressive Lymphoma: A 6-Year Single Center Retrospective Analysis 104
Hepatic, gastric and bone marrow AL amyloidosis that began with Budd-Chiari syndrome: a case report 99
AL amyloidosis: an overview on diagnosis, staging system, and treatment 99
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety 99
Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment 98
A rare case of solitary plasmacytoma mimicking submucosal lesion of ascending colon: a case report and literature review 97
Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy 96
Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences 94
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study 93
Clinicians’ Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy 92
Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights 91
Long-Term Survival with Multiple Myeloma: An Italian Experience 91
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma 90
Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review 90
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 89
Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group 87
Monoclonal antibodies: Leading actors in the relapsed/refractory multiple myeloma treatment 81
The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management 79
Plasma cell leukemia: first diagnostic approach in the laboratory|Leucemia plasmacellulare: primo inquadramento diagnostico in laboratorio 77
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments 68
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 64
Sequential Bispecific Antibodies in Functional and Clinical High Risk Multiple Myeloma, Manifesting with Extramedullary Disease at Relapse: A Case Report 64
Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma Patients 60
Novel Experimental Drugs for Treatment of Multiple Myeloma 54
Infection events in patients with newly diagnosed multiple myeloma with anti-CD38 monoclonal antibody-based first line regimens: A multicentric Italian experience 52
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy 41
The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice? 11
Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy 10
Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life Application 2
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone 2
Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape 1
Totale 3.800
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.542
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.542
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202232 0 0 0 0 0 0 10 0 6 2 7 7
2022/202372 8 7 8 3 5 3 0 3 16 0 13 6
2023/2024190 22 3 7 5 22 6 3 6 8 8 26 74
2024/2025783 65 36 20 11 16 77 86 29 162 87 89 105
2025/20262.723 215 230 461 300 267 213 459 203 178 197 0 0
Totale 3.800